Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs NIO Inc. (NIO) Price & Performance

Ascendis Pharma A/STrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs NIO Inc. — how do they compare? Ascendis Pharma A/S trades at $255.66 (market cap $16.67B), while NIO Inc. trades at $4.58 (market cap $11.59B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.

ASNDNIO
Market Cap
$16.67B$11.59B
Sector
HealthConsumer Cyclical
52-Week High
$277.18$7.89
52-Week Low
$189.74$4.44
Enterprise Value
$17.04B$10.82B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.

ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.

NIO Inc.

NIO trades at $4.82, up 1.69% today, showing recent volatility amid mixed market signals. The company reported July 2026 deliveries growth and has beaten earnings expectations for three consecutive quarters, though it remains unprofitable with a net income margin of -9.09%. Technical indicators show neutral momentum with RSI at neutral levels, while analyst sentiment leans bullish with 54% buy ratings.

NIO presents a high-risk growth opportunity with improving revenue trends but persistent losses. The stock offers potential upside if profitability improves, but faces significant execution risks in the competitive EV market. Investors should weigh strong delivery growth against cash burn and negative equity returns before considering position entry.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About NIO Inc.

NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.

Read more on NIO